Week 83: a bit fatigue and an interesting research article

Written by Lars Haakon Soraas
26
Mar

Week 83 in the war on cancer has passed. Here is an update:

  • Dyanne continues to have a bit fatigue.
  • She has reached the maximum dose she is supposed to take of tetrathiomolybdate. If this drug is what is causing the fatigue, then hopefully the fact that she now does not need to increase the dose further will help reduce the fatigue.

Tomorrow we are going to a a conference on lung cancer organized by the Norwegian Lung Cancer Society. It is a whole day conference and it takes place downtown Oslo. Here are more details: https://www.facebook.com/events/428196550855591/. Participation is free. If you want to learn a bit more about lung cancer, drop by!

This week I also happened to come across a very interesting research article. In short: researchers in China and the US developed a personalized vaccine for a Chinese lung cancer patient who had an EGFR L858R mutation (Dyanne has a slightly different mutation: EGFR exon 19 deletion). The vaccine was very similar to the vaccine Dyanne is getting in Germany. The cancer in the lungs of the patient rapidly shrank after he started the vaccine injections. Unfortunately, the patient died due to a growing lesion in/near the liver. However, the fact that most of the cancer shrunk is very encouraging. The experience of this Chinese patient indicates that other lung cancer patients who have the EGFR L858R mutation potentially may also benefit from such a vaccine. So: if you, or someone you know, has lung cancer and the EGFR L858R mutation, then I would strongly encourage you to read this article: Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. If you are interested in trying to implementing it, I probably know someone who can help. So don’t hesitate to reach out ().

Happy Sunday night everyone!

Follow this blog

Get every new post delivered right to your inbox.